Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

ESMO 2020

PARP inhibition is moving on from breast and ovarian cancer to the treatment of patients with prostate cancer and BRCA1/2 mutation. Olaparib (Lynparza) reduced the risk for death by 31% versus enzalutamide (Xtandi) or abiraterone (Zytiga) in men with metastatic castration-resistant prostate cancer (CRPC) and BRCA1 or BRCA2, and to a lesser extent ATM mutations, according to the final analysis of the phase 3 PROfound trial.
Adding the oral cyclin-dependent kinase (CDK)4/CDK6 inhibitor abemaciclib (Verzenio) to endocrine therapy led to a significant reduction in the risk for invasive disease recurrence versus endocrine therapy alone in patients with high-risk hormone receptor (HR)-positive, HER2-negative early-stage breast cancer, according to findings from the phase 3 monarchE clinical trial. The results were presented at the 2020 European Society for Medical Oncology (ESMO) virtual meeting and were featured at the meeting press conference.
The combination of cabozantinib (Cabometyx), a second-generation tyrosine kinase inhibitor (TKI), plus nivolumab (Opdivo), an immune checkpoint inhibitor, significantly improved overall survival (OS) and doubled the objective response rates (ORR) compared with the current standard, sunitinib (Sutent), in treatment-naïve patients with advanced renal-cell carcinoma (RCC), according to the results of the phase 3 CheckMate-9ER clinical trial.
Adding abemaciclib to endocrine therapy led to a significant reduction in invasive disease recurrence versus endocrine therapy alone in HR-positive, HER2-negative early-stage breast cancer, according to the results of a new study. “This is a very important trial, and the findings will change practice,” said Giuseppe Curigliano, MD, PhD.
For patients with recurrent ovarian cancer progressing within 6 to 12 months after their last platinum line, a combination of trabectedin and pegylated liposomal doxorubicin (PLD) did not demonstrate superiority over a combination of carboplatin and PLD.
XMT-1536 is an antibody-drug conjugate that targets the sodium-phosphate cotransporter NaPi2b, which is commonly expressed in solid tumors such as high-grade serous ovarian cancer. Treatment with XMT-1536 results in an overall response rate of 34% in patients with advanced disease; antitumor activity is positively correlated with a higher NaPi2b expression.
Page 1 of 3
Results 1 - 10 of 28